Last mentioned: Mar 7, 2026
Institutional analysts are intensifying their scrutiny of Figma and DaVita as both companies navigate pivotal transitions in the SaaS and healthcare sectors. While Figma solidifies its post-IPO independence through AI-driven design tools, DaVita is increasingly leveraging cloud-based predictive analytics to maintain its dominance in the dialysis market.
Figma (FIG) faces a critical public market test as it balances an OpenAI-driven product pivot against insider selling and 'moat' skepticism. Meanwhile, DaVita (DVA) remains a benchmark for defensive value, highlighting the ongoing tension between high-growth SaaS and stable healthcare assets in institutional portfolios.
Investors are weighing the defensive stability of healthcare giant DaVita against the high-growth potential of newly public Figma. While DaVita offers a moat-protected cash flow model favored by value investors, Figma represents the next frontier of collaborative AI-driven design tools.